Umbilical metastases: Real-world data shows abysmal outcome.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
15 09 2021
Historique:
revised: 05 04 2021
received: 23 10 2020
accepted: 29 04 2021
pubmed: 16 5 2021
medline: 14 9 2021
entrez: 15 5 2021
Statut: ppublish

Résumé

Umbilical metastases form a clinical challenge, especially when they represent the first sign of malignant disease and the primary tumor is unknown. Our study aims to generate insight into the origin and timing of umbilical metastasis, as well as patient survival, using population-based data. A nationwide review of pathology records of patients diagnosed with an umbilical metastasis between 1979 and 2015 was performed. Data was collected from the Nationwide Network and Registry of Histopathology and Cytopathology (PALGA) and the Netherlands Cancer Registry. Kaplan-Meier analyses and log-rank testing were used to estimate overall survival and a Cox proportional hazard model was used to determine multivariable hazard ratios. A total of 806 patients with an umbilical metastasis were included. There were 210 male (26.1%) and 596 female (73.9%) patients. Distribution of umbilical metastases was different between male and female patients due to the high incidence of umbilical metastases originating from the ovaries in females. They most frequently originated from the ovaries in female patients (38.8%) and from the colon in male patients (43.8%). In 18% of cases no primary tumor could be identified. Prognosis after diagnosis of an umbilical metastasis was dismal with a median survival of 7.9 months (95% confidence interval 6.7-9.1). The origin of the primary tumor was an independent prognostic factor for overall survival. In conclusion, umbilical metastases relatively rare, mainly originating from intraabdominal primary tumors. Survival is dependent on the origin of the primary tumor and poor overall survival rates warrant early recognition.

Identifiants

pubmed: 33990961
doi: 10.1002/ijc.33684
pmc: PMC8361932
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1266-1273

Informations de copyright

© 2021 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Références

Eur J Cancer. 2018 Sep;101:77-86
pubmed: 30031970
Eur J Surg Oncol. 1997 Apr;23(2):186-7
pubmed: 9158198
Cell Oncol. 2007;29(1):19-24
pubmed: 17429138
Int J Cancer. 2021 Sep 15;149(6):1266-1273
pubmed: 33990961
Int J Dermatol. 1998 Jan;37(1):7-13
pubmed: 9522229
Med J Aust. 1986 Nov 3;145(9):477-8
pubmed: 3773838
World J Gastrointest Surg. 2013 Oct 27;5(10):272-7
pubmed: 24179626
J Am Acad Dermatol. 1984 Apr;10(4):610-5
pubmed: 6715609
Gynecol Oncol. 2012 Jun;125(3):649-54
pubmed: 22370602
Eur J Cancer. 2017 Apr;75:3-4
pubmed: 28214423
Int J Cancer. 2018 Dec 1;143(11):2758-2766
pubmed: 30095162
World J Surg Oncol. 2005 Feb 21;3(1):13
pubmed: 15723695

Auteurs

Niek Hugen (N)

Department of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands.
Department of Surgery, Rijnstate Hospital, Arnhem, The Netherlands.

Heleen Kanne (H)

Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.

Femke Simmer (F)

Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.

Carlijn van de Water (C)

Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.

Quirinus J Voorham (QJ)

PALGA Foundation, Houten, The Netherlands.

Vincent K Ho (VK)

Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.

Valery E Lemmens (VE)

Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.

Michiel Simons (M)

Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.

Iris D Nagtegaal (ID)

Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH